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Abstract
Introduction: In vivo and in vitro evidence suggests that adenosine and its agonists play key roles
in the process of ischemic preconditioning. The effects of low-dose adenosine infusion on ischemic
preconditioning have not been thoroughly studied in humans.
Aims: We hypothesised that a low-dose adenosine infusion could reduce the ischemic burden
evoked by physical exercise and improve the regional left ventricular (LV) systolic function.
Materials and methods: We studied nine severely symptomatic male patients with severe
coronary artery disease. Myocardial ischemia was induced by exercise on two separate occasions
and quantified by Tissue Doppler Echocardiography. Prior to the exercise test, intravenous low-
dose adenosine or placebo was infused over ten minutes according to a randomized, double blind,
cross-over protocol. The LV walls were defined as ischemic if a reduction, no increment, or an
increment of < 15% in peak systolic velocity (PSV) was observed during maximal exercise
compared to the baseline values observed prior to placebo-infusion. Otherwise, the LV walls were
defined as non-ischemic.
Results: PSV increased from baseline to maximal exercise in non-ischemic walls both during
placebo (P = 0.0001) and low-dose adenosine infusion (P = 0.0009). However, in the ischemic walls,
PSV increased only during low-dose adenosine infusion (P = 0.001), while no changes in PSV
occurred during placebo infusion (P = NS).
Conclusion: Low-dose adenosine infusion reduced the ischemic burden and improved LV regional
systolic function in the ischemic walls of patients with exercise-induced myocardial ischemia,
confirming that adenosine is a potential preconditioning agent in humans.
Introduction
Ischemic preconditioning protects the heart through brief
episodes of ischemia and renders the myocardium resist-
ant to subsequent ischemic insults. The potential benefi-
cial effects of ischemic preconditioning include the
preservation of the left ventricular (LV) systolic and
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diastolic functions[1], the preservation of adenosine tri-
phosphate levels in myocardial biopsy specimens[1], and
the prevention of arrhythmias by minimizing QT and JT
dispersion[2].
Ischemic preconditioning is triggered by the binding of
several humoral factors such as adenosine, bradykinin,
and opioids to their cardiac receptors[3,4], thereby initiat-
ing a series of complex and divergent signal cascades that
eventually converge on protein kinase C. The cardiopro-
tective effect of ischemic preconditioning seems to be
biphasic, with an early opioid mediated phase occurring
within minutes from the initial ischemic insult and lasting
for two to three hours, and a late phase becoming appar-
ent 12 to 24 hours later, lasting three to four days and
requiring de novo protein synthesis[3,4]. The major cellu-
lar mechanism responsible for the beneficial effects of
ischemic preconditioning seems to be the opening of KATP
channels either on the cardiac sarcolemmal or mitochon-
drial membrane [5-7].
The aim of this study was to explore whether low-dose
adenosine infusion exerts an ischemic preconditioning




We studied nine male patients, mean age 74 years, (range
58-79 years), with severe coronary artery disease (eight
with three-vessel and one with two-vessel disease) and
severely symptomatic (CCS angina functional class II-III).
Except for one patient who had dynpnea, the rest suffered
from daily angina. Eight of the patients underwent later
coronary bypass grafting (CABG) and one patient with
earlier CABG underwent percutanous coronary interven-
tion. All patients had normal global LV systolic function
at rest except for one patient who had mildly depressed
global LV systolic function (LV ejection fraction ≈ 45%).
Three patients had a history of myocardial infarction,
three had a history of systemic arterial hypertension, three
had a history of paroxysmal atrial fibrillation, three had a
mild form of chronic renal failure, and none had a history
of diabetes mellitus. All patients were treated with aspirin,
beta-blockers, long acting nitrates and calcium channel
blockers and seven with either angiotensine converting
enzyme inhibitors or angiotensine II receptors blockers.
Standard echocardiography
We obtained a baseline two-dimensional echocardiogra-
phy with superimposed Tissue Doppler Echocardiography
(TDE) images using a multi-Hertz transducer with com-
mercially available equipment (Vivid 7, GE Vingmed,
Horten, Norway) for all patients prior to bicycle exercise
stress echocardiography test. Standard parasternal short
and long axis views, as well as apical two, three, and four
chamber views, were digitized during three consecutive
cardiac cycles in cine loop format for off-line analysis.
Exercise stress echocardiography test protocol
The patients underwent two separate exercise stress
echocardiography test in semi-supine position on a spe-
cially designed, table-mounted bicycle ergometer. The ini-
tial workload was 25 Watts with increments of 10 Watts
added every minute. At each stage, the heart rate, systolic
blood pressure, and a 12-lead ECG were recorded. We
obtained standard echocardiographic images of five con-
secutive cardiac cycles containing TDE information at rest,
sub-maximal workload (heart rate = 70% of the expected
maximal heart rate), maximal workload, and recovery
phases (one to two minutes after the exercise); all meas-
urements were digitally recorded and stored. Stopping cri-
teria for exercise test was either severe chest pain or
achieved 85% of maximal expected heart rate (220-age).
Study protocol
An intravenous infusion of either low-dose adenosine (35
μg/kg/min) or placebo (saline infusion) was given in a
double-blind fashion over 10 minutes prior to the start of
the exercise test. The order of the drug administration was
randomly selected and the sequence of infusions was
inverted on the second occasion; the first and second
occasions occurred at least one day apart, median 3 days
(range 1 to 5 days) (Figure 1). The rationale to select this
dosage lies on previous studies showing that it had an
analgetic effect[8], doses between 50 and 70 μg/kg/min
may have a positive effect while doses higher than 70 μg/
kg/min provoked ischemia[9] in patients with coronary
artery disease.
Tissue Doppler echocardiography off-line analysis
The analysis of the echocardiographic images was done by
one of the investigators (MQ) blinded to the sequence of
drug administration. However, the images corresponding
to each stage of the protocol were known as the heart rate
at rest and at peak exercise were clearly discernible. A sam-
ple volume was positioned on the region of interest at the
basal segment of the four LV walls (septal, lateral, inferior,
and anterior) to obtain a myocardial velocity profile (Fig-
ure 2). We analyzed both the systolic and diastolic phases
of the velocity profile. We defined peak systolic velocity
(PSV) as the peak velocity during ejection. We also meas-
ured peak velocity at early diastole (E'-wave) and peak
velocity at the late diastole (A'-wave). The longitudinal A-
V plane displacement was calculated by time integration
of the PSV. In addition, the degree of myocardial compres-
sion/deformation as strain (S) and strain rate (SR) were
also calculated.Cardiovascular Ultrasound 2009, 7:52 http://www.cardiovascularultrasound.com/content/7/1/52
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In order to assess the LV regional systolic function and to
detect the presence of regional myocardial ischemia, the
LV walls were categorized as ischemic or non-ischemic: a
LV wall was defined as ischemic if a reduction, no incre-
ment, or an increment of <15% in PSV, was observed dur-
ing maximal work load compared to baseline preceding
placebo-infusion; otherwise, the LV walls were defined as
non-ischemic.
Statistical Analysis
Data are presented as mean ± standard deviation (SD).
Statistical comparisons were performed by analysis of var-
iance (ANOVA) with repeated measures. Post hoc com-
parisons between groups were performed using the Tukey
test.
Ethics
The local Ethics Committee at the Karolinska University
Hospital, Huddinge, approved the study. All participants
gave written informed consent.
Results
There were no significant differences in maximal work
capacity, hemodynamic parameters including heart rate
Study protocol Figure 1
Study protocol. The dotted lines represent absence of infusion either of placebo or of adenosine. Echocardiographic images 
were obtained before adenosine/placebo infusions and at each stage of the exercise test.
Tissue Doppler echocardiography Figure 2
Tissue Doppler echocardiography. To the left, an apical four-chamber view picture with the sample volume placed at the 
basal portion of the septal wall. On the right, all the variables extracted from on-line recording.Cardiovascular Ultrasound 2009, 7:52 http://www.cardiovascularultrasound.com/content/7/1/52
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and blood pressure or ST-depression (Table 1). We
observed a significant increment in PSV during maximal
stress compared to rest during both the adenosine and
placebo infusions; however, we observed no significant
differences in PSV between low-dose adenosine and pla-
cebo infusions (Table 1).
According to the pre-defined criteria, 12 of the 36 LV walls
in the nine patients were found to be ischemic during the
placebo infusion. When milder criteria were used to
define LV wall ischemia, i.e. a reduction, no increment, or
an increment of <25% in peak systolic velocity, 15 of the
36 LV walls were found to be ischemic.
In the ischemic walls, the increment in PSV was higher
during adenosine infusion as compared to placebo (P <
0.001; Figure 3). The same pattern was seen in AV-plane
displacement during systole, and E'-wave (Table 2). There
were no significant differences in A'-wave and strain rate
according to the ischemic response during low-dose ade-
nosine infusion or placebo (Table 2).
Discussion
In this study, a low-dose infusion of adenosine preserved
the regional systolic function of LV walls subjected to an
exercise-induced ischemic burden. We observed a higher
PSV at peak exercise in LV walls rendered ischemic during
adenosine infusion than during placebo infusion, sug-
gesting a preconditioning effect of adenosine. The main
idea of the study was to investigate the possible precondi-
tioning effect of adenosine infusion in a quantitative
manner and thus avoiding any possible bias induced by
subjective analysis of wall motion analysis. Therefore, we
did not use wall motion score in the diagnosis of myocar-
dial ischemia. The concordance between wall motion core
and tissue Doppler imaging in this respect has been
reported elsewhere [10]. Having said this, we do not mean
that quantitative stress echocardiography is the gold
standard for the detection of myocardial ischemia.
Alternative mechanisms for preserving the regional systo-
lic function may have been achieved by adenosine-medi-
ated vasodilatation or by the possible unloading effects of
adenosine; however, these are unlikely mechanisms
because myocardial ischemia would already have caused
maximal vasodilatation and the low-dose adenosine infu-
sion was stopped before the exercise stress test, by which
time any previously infused adenosine would have been
metabolised and could not have had a vasodilatory effect.
In addition, heart rate and blood pressure responses did
not differ between the two treatments, excluding the pos-
sible unloading effect of adenosine.
Adenosine has been suggested to induce precondition-
ing[11] by agonizing its A1 and A3 receptors; however,
some of the protective effects of adenosine might occur
via an antiplatelet effect or an anti-inflammatory effect
that is totally independent of preconditioning. Clinical
trials suggest that some preconditioning mimetics reduce
myocardial infarct size when given in conjunction with
reperfusion [12,13], and may improve survival, especially
in selected patients with acute anterior myocardial infarc-
tion[14]. It should be noted that the largely neutral effects
observed in the AMISTAD study refers to the possible pre-
conditioning effect of adenosine in a different clinical set-
ting, namely the "reperfusion-injury" provoked by
opening the infarct related artery in the context of an ST-
elevation acute myocardial infarction.
Table 1: Hemodynamic parameters (heart rate, blood pressure), work capacity (Watts) and Tissue Doppler echocardiography 
variables (expressed as the average of the four LV walls) measured at baseline and maximal work loud during adenosine and placebo 
infusions
Adenosine Placebo
Variables Baseline Peak Baseline Peak
Heart rate, bpm 59 ± 11 104 ± 13* 62 ± 14 106 ± 13*
SBP, mm Hg 143 ± 12 172 ± 18* 148 ± 20 169 ± 28*
Watts 00.0 ± 0.0 83 ± 19 00.0 ± 0.0 83 ± 28
ST depression 1.8 ± 1.4 1.4 ± 1.0
PSV, cm/s 5.5 ± 1.6 6.4 ± 3.2* 5.5 ± 1.6 7.6 ± 2.6*
A-V plane, mm 9.6 ± 2.7 10.9 ± 4.4* 9.0 ± 2.6 11.7 ± 4.3*
S% 17.4 ± 5.1 23.4 ± 7.4* 16.5 ± 3.8 22.1 ± 7.2*
SR-1 -0.9 ± 0.3 -1.9 ± 0.5* -1.0 ± 0.2 -1.9 ± 1.5*
E'-wave, cm/s 6.5 ± 1.9 8.8 ± 4.0* 5.5 ± 2.3 8.5 ± 4.2*
A'-wave, cm/s 4.9 ± 2.4 5.1 ± 3.6 4.9 ± 2.5 4.1 ± 2.9
Values are expressed as means ± SD.
Abbreviations: A' = late diastolic A-wave; A-V = atrio-ventricular plane displacement; bpm = beats per minute; E' = early diastolic E-wave; PSV = 
peak systolic velocity; SBP = systolic blood pressure, S% = strain; SR = strain rate.
* P < 0.01 Peak versus baselineCardiovascular Ultrasound 2009, 7:52 http://www.cardiovascularultrasound.com/content/7/1/52
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In the present experimental model of exercise induced
myocardial ischemia detected by TDE technique in
humans, it is impossible to be sure that the reported find-
ings were caused by ischemic preconditioning mediated
by the activation of adenosine receptors; however exclud-
ing the vascular and unloading effects and considering
that infusion of 35 μg/kg/min of adenosine give rise to
activation of adenosine receptors[15], the hypothesis of
ischemic preconditioning induced by adenosine is highly
plausible. Our results are in keeping with Picano et al who
by using dipyridamole, which is an adenosine uptake
inhibitor reported increased ischemic threshold [16].
Numerous studies have shown that pre-infarction angina
pectoris protects patients who develop acute myocardial
infarction [17-19], and at least part of this benefit may be
due to a preconditioning phenomenon rather than simply
recruiting collateral blood flow. Pre-infarction angina pec-
toris has been associated with smaller myocardial infarct
size, decreased prevalence of congestive heart failure, less
cardiac death, fewer arrhythmias, and improved cardiac
function[18]. Therefore, it might be possible to treat high
risk patients or patients with unstable angina pectoris
with preconditioning mimetic agents that stimulate the
biochemistry of preconditioning without actually causing
ischemia.
Study limitations
The small size of this study precludes the extrapolation of
our results to all patients with ischemic heart disease,
especially to those with mild forms of exercise-induced
ischemia. The positive pre-conditioning effects of adenos-
ine were not observed for all parameters reflecting the
regional LV systolic function. In fact, strain rate, a measure
of "pure" myocardial contractility, was not affected by
adenosine. This result could be explained by the low
reproducibility of this measure when assessed during exer-
cise[20].
Certainly, some degree of ischemic preconditioning
induced by angina pectoris did exist among all the
patients. However, we do not believe that this fact com-
promised the results of the study, considering the pla-
cebo/controlled and the cross-over character of the study.
We used high ischemic limit criteria to define myocardial
ischemia by tissue Doppler echocardiography, and when
milder criteria that allow for the detection of less severe
forms of ischemia were applied, the results were the same.
However, if we applied the same ischemic criteria as are
used in clinical practice[21], almost all LV walls were cat-
egorized as ischemic, making it impossible to perform
adequate statistical analysis. This fact emphasizes that we
were studying patients with severe coronary artery disease:
severely symptomatic and with severe exercise induced
myocardial ischemia.
Possible clinical implications
The present results may open the possibilities of testing
new therapeutic agents for the treatment of not only high
risk patients with preconditioning mimetics that stimu-
late the biochemistry of preconditioning without actually
causing ischemia but also of a vast number of patients
with stable angina pectoris with mild to severe symptom
in whom coronary revascularisation is impossible or not
achievable.
Conclusion
Low-dose adenosine infusion reduced the ischemic bur-
den and improved the left ventricular regional systolic
function in the ischemic walls of patients with exercise-
induced myocardial ischemia, confirming the possible
preconditioning effect of adenosine in humans.
Table 2: Tissue Doppler echocardiography of ischemic and non ischemic LV walls during baseline and maximal work loud during low 
dose adenosine and placebo infusions
Adenosine Pacebo
Variables Ischemic walls Non ischemic walls Ischemic walls Non ischemic walls
Rest Peak Rest Peak Rest Peak Rest Peak
PSV, cm/s 5.1 ± 1.4 6.9 ± 2.1*¥ 5.6 ± 1.9 7.3 ± 2.7* 6.0 ± 2.0 5.6 ± 1.6 5.4 ± 1.5 9.1 ± 2.7*
A-V plane, mm 9.4 ± 2.6 10.3 ± 3.2*¥ 10.3 ± 3.7 11.6 ± 5.8* 10.7 ± 2.2 9.7 ± 2.7 8.4 ± 3.2 13.0 ± 5.4*
S% 16 ± 3 24 ± 4 16 ± 6 23 ± 12* 17 ± 4 13 ± 5 16 ± 6 27 ± 5*
SR-1 -1.0 ± 0.9 -1.7 ± 1.3* -1.4 ± 0.5 -2.0 ± 1.0* -1.6 ± 0.5 -0.9 ± 1.6 -1.2 ± 0.5 -2.6 ± 1.8*
E'-wave, cm/s 7.4 ± 3.7 11.9 ± 5.4*¥ 6.4 ± 2.7 10.1 ± 2.4* 7.8 ± 2.3 9.7 ± 5.9* 5.2 ± 2.6 10.4 ± 3.7*
A'-wave, cm/s 6.7 ± 1.6 7.3 ± 2.9 4.3 ± 2.6 6.7 ± 1.9* 6.6 ± 1.5 6.1 ± 1.7* 4.0 ± 2.0 7.1 ± 1.5*
Values are expressed as means ± SD.
As in table 1
* P < 0.01 Peak versus baseline
¥ P < 0.01 Peak - ischemic walls - adenosine, versus peak - ischemic walls - placeboCardiovascular Ultrasound 2009, 7:52 http://www.cardiovascularultrasound.com/content/7/1/52
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